Skip to main content

Bamlanivimab reduces risk of COVID in skilled nursing homes and assisted living facilities, study finds

July 21, 2021

UNC’s Institute of Global Health and Infectious Diseases Director Myron Cohen, MD, is the lead investigator of a study recently published in the Journal of the American Medical Association (JAMA) that shows bamlanivimab monotherapy reduced the incidence of infection in skilled nursing homes and assisted living facilities with high risk of SARS-CoV-2 exposure. The randomized phase 3 clinical trial … Continued

UNC investigators help prove a monoclonal antibody prevents, treats COVID-19 in nursing homes

January 21, 2021

  Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network (CoVPN). … Continued

Taking the long view: Cohen delivers Richardson Lecture

October 13, 2020

Human beings will continue to suffer from infectious diseases, some of them contagious. To fight a new disease, infectious disease physicians first work to determine the rules that govern the disease, its spread, and the gravity of the infection. Those rules then determine our prevention and treatment strategies, Institute Director Myron Cohen, MD, told his … Continued

NIH awards Cohen, FHI $9.2 million for development of COVID prevention studies

July 21, 2020

The National Institutes of Health has awarded Myron Cohen, MD, director of UNC’s Institute for Global Health and Infectious Diseases, and FHI 360 $9.2 million to support research through the new COVID Prevention Network (CoVPN). The National Institute of Allergy and Infectious Diseases at the National Institutes of Health has formed the network to better … Continued